布洛芬 (24 h) 抑制 COX-1 和 COX-2 活性，IC50 值为 13 μM 和 370 μM[1]。在 AGS 细胞（胃腺癌细胞系）中，布洛芬（500 μM，48 小时）会导致细胞凋亡并抑制血管生成和细胞增殖[2]。在 AGS 细胞中，布洛芬（500 μM，48 小时）会增加野生型 P53 和 Bax 基因的 RNA 水平，但下调 Akt、VEGF-A、PCNA、Bcl2、OCT3/4 和 CD44 基因的转录[2]。在原代 CF 鼻上皮细胞和囊性纤维化 (CF) 细胞模型中，布洛芬（500 μM，24 小时）可导致微管延伸至细胞外周，并恢复微管依赖性细胞内胆固醇转运[3]。通过光敏化过程，布洛芬（500 μM，24 小时）会增加 MCF-7 和 MDA-MB-231 细胞中紫外线诱导的细胞死亡[4]。

在产后乳腺癌模型中，布洛芬（300 mg/kg；口服；每天，持续 14 天）可减少总体肿瘤生长并改善抗肿瘤免疫功能，而不会引起有害的自身免疫反应[5]。 ？在慢性奥沙利铂模型的大鼠中，布洛芬（60 mg/kg；ih；每隔一天，持续 15 天）是否会降低导致周围神经病变的神经病变风险[6]。布洛芬（20 mg/kg；口服；每12小时一次，共5剂）可降低平均肌纤维横截面积，但不会改变冈上肌腱对运动的适应调节[7]。 ?在持续性肺部感染的大鼠模型中，布洛芬（35 mg/kg；口服；每日两次）可减少对铜绿假单胞菌的炎症反应[8]。

细胞活力测定[2]
细胞类型： AGS 细胞
测试浓度： 100-1000 μM
孵育时间： > 24 小时、48 小时
实验结果： 抑制 AGS 细胞活力，IC50 值为 630 μM（台盼蓝染色，24 小时）、456 μM（中性红测定，24 小时）、549 μM（台盼蓝染色，48 小时）和 408 μM（中性红测定，48 小时）。

Animal/Disease Models: Syngeneic (D2A1) orthotopic Balb/c mouse model of PPBC (postpartum)[5]
Doses: 300 mg/kg, daily for 14 days
Route of Administration: Fed in animal feedings (added to pulverized standard chow and mixed dry , then mixed with water, made into chow pellets and dried thoroughly)
Experimental Results: Suppresed tumor growth, decreased presence of immature monocytes and increased numbers of T cells. Enhanced Th1 associated cytokines as well as promoted tumor border accumulation of T cells.

---

Animal/Disease Models: Oxaliplatin‑induced peripheral neuropathy[6]
Doses: 60 mg/kg, every second day for 15 days
Route of Administration: subcutaneous (sc) injection
Experimental Results: Lowered sensory nerve conduction velocity (SNCV).

[1]. Noreen Y, et al. Development of a radiochemical cyclooxygenase-1 and -2 in vitro assay for identification of natural products as inhibitors of prostaglandin biosynthesis. J Nat Prod. 1998 Jan;61(1):2-7.
[2]. Hassan Akrami, et al. Inhibitory effect of ibuprofen on tumor survival and angiogenesis in gastric cancer cell. Tumour Biol. 2015 May;36(5):3237-43.
[3]. Sharon M Rymut, et al. Ibuprofen regulation of microtubule dynamics in cystic fibrosis epithelial cells. Am J Physiol Lung Cell Mol Physiol. 2016 Aug 1;311(2):L317-27.
[4]. Emmanuelle Bignon, et al. Ibuprofen and ketoprofen potentiate UVA-induced cell death by a photosensitization process. Sci Rep. 2017 Aug 21;7(1):8885.
[5]. Nathan D Pennock, et al. Ibuprofen supports macrophage differentiation, T cell recruitment, and tumor suppression in a model of postpartum breast cancer. J Immunother Cancer. 2018 Oct 1;6(1):98.
[6]. Thomas Krøigård, et al. Protective effect of ibuprofen in a rat model of chronic oxaliplatin-induced peripheral neuropathy. Exp Brain Res. 2019 Oct;237(10):2645-2651.
[7]. Sarah Ilkhanipour Rooney, et al. Ibuprofen Differentially Affects Supraspinatus Muscle and Tendon Adaptations to Exercise in a Rat Model. Am J Sports Med. 2016 Sep;44(9):2237-45.
[8]. M W Konstan, et al. Ibuprofen attenuates the inflammatory response to Pseudomonas aeruginosa in a rat model of chronic pulmonary infection. Implications for antiinflammatory therapy in cystic fibrosis. Am Rev Respir Dis. 1990 Jan;141(1):186-92.

C13H18O2

206.28

15687-27-1

(S)-(+)-Ibuprofen;51146-56-6;(S)-(+)-Ibuprofen-d3;1329643-44-8;(R)-(-)-Ibuprofen;51146-57-7;Ibuprofen sodium;31121-93-4;Ibuprofen-d3;121662-14-4;Ibuprofen-d4;Ibuprofen-13C6;1216459-54-9;Ibuprofen L-lysine;57469-77-9;Ibuprofen-13C,d3;1261394-40-4

O([H])C(C([H])(C([H])([H])[H])C1C([H])=C([H])C(=C([H])C=1[H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])[H])=O

HEFNNWSXXWATRW-UHFFFAOYSA-N

InChI=1S/C13H18O2/c1-9(2)8-11-4-6-12(7-5-11)10(3)13(14)15/h4-7,9-10H,8H2,1-3H3,(H,14,15)

2-[4-(2-methylpropyl)phenyl]propanoic acid

Ibuprofen, Advil, Motrin, Nurofen, Brufen

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Solubility in Formulation 1: ≥ 2.5 mg/mL (12.12 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL.
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.

---

Solubility in Formulation 2: ≥ 2.5 mg/mL (12.12 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.

---

View More

Solubility in Formulation 3: ≥ 2.5 mg/mL (12.12 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.

---

Solubility in Formulation 4: 1% DMSO+30% polyethylene glycol+1% Tween 80: 20 mg/mL

---

请根据您的实验动物和给药方式选择适当的溶解配方/方案：
1、请先配制澄清的储备液(如：用DMSO配置50 或 100 mg/mL母液(储备液));
2、取适量母液，按从左到右的顺序依次添加助溶剂，澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明，并不一定代表此产品 的实际溶解配方):
10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline);
假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀/澄清；向上述体系中加入50 μL Tween-80，混合均匀/澄清；然后继续加入450 μL ddH2O (或 saline)定容至 1 mL；
3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例;
4、 如产品在配制过程中出现沉淀/析出，可通过加热(≤50℃)或超声的方式助溶;
5、为保证最佳实验结果，工作液请现配现用！
6、如不确定怎么将母液配置成体内动物实验的工作液，请查看说明书或联系我们;
7、 以上所有助溶剂都可在 Invivochem.cn网站购买。